This from December:
Botanix Pharmaceuticals (BOT) receives confirmation from the US FDA that its new drug application (NDA) for its sofpironium bromide product is formally in review. The FDA confirms it identified no filing review issues in the company’s NDA, and the application was sufficiently complete to permit substantive review. Further, it confirms that an advisory committee meeting is not needed to discuss the application. A mid-cycle review remains on track for Q1 2023, and Botanix says this means approval for the product is still on track for the September quarter of next year
BOT - Anything but charting, page-3605
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.5¢ | $1.940M | 6.061M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 470483 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 33000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |